JAKs (Janus kinases) are essential mediators of almost all biological signalling events initiated by haemopoietic and immune cytokines. However, aberrant and/or prolonged JAK-induced signalling is detrimental and can give rise to a number of inflammatory and proliferative pathologies. For this reason, the tyrosine kinase activity of the JAKs is carefully regulated at a number of different levels. Primarily, this is achieved by: (i) ensuring that the catalytic domain is 'switched off' under basal conditions, and (ii) inhibiting the activity of JAK after it has been switched on. Whereas the first mode of inhibition is mediated by JAK's own pseudokinase domain as well as the action of phosphatases, the second is achieved by the action of the SOCS (suppressor of cytokine signalling) proteins, negative-feedback inhibitors of JAK-mediated signalling. The present review focuses on the mode of action of SOCS1 and SOCS3, the two most potent JAK inhibitors.
Introduction
Cytokines signal by binding to specific cell-surface receptors on their target cell. The cytoplasmic domains of these cytokine receptors are bound by one or more members of the JAK (Janus kinase) family [1, 2] . Before cytokine stimulation these JAKs are found in an 'inactive' state. Cytokine exposure leads to a change in the conformation and/or oligomeric state of the receptor which allows transactivation of JAKs [3, 4] . Once activated, JAKs phosphorylate the receptor and subsequently the STAT (signal transducer and activator of transcription) family of transcription factors. STATs are normally sequestered in the cytoplasm, but, once phosphorylated, they dimerize and translocate into the nucleus, where they up-regulate transcription of the appropriate genes and thereby effect the appropriate biological response [2, 5] .
Negative-feedback inhibition of JAK-mediated signalling: the SOCS family
As part of the response to cytokine stimulation, STATs directly up-regulate the transcription of SOCS (suppressor of cytokine signalling) proteins [6] [7] [8] [9] , which inhibit the signalling cascade, creating a negative-feedback loop (Figure 1 ). This prevents prolonged cytokine signalling, which could result in chronic inflammation and promote aberrant proliferation and tumorigenesis.
There are eight classical SOCS proteins encoded in the human genome: SOCS1-SOCS7 and CIS [cytokineinducible SH2 (Src homology 2) domain-containing protein] [6] . All contain a central SH2 domain and a short C-terminal domain termed the 'SOCS box'. The SOCS box recruits the E3 ubiquitin ligase scaffold Cullin5 [10, 11] , which then catalyses the ubiquitination of phosphorylated signalling intermediates bound to the SOCS SH2 domains [12] [13] [14] . These substrates are presumed to include both the JAKs themselves as well as the cytokine receptors to which they are bound, although, to date, there are few validated targets for SOCS-mediated ubiquitination [12] .
The two most potent suppressors of cytokine signalling are SOCS1 and SOCS3. In addition to ubiquitin ligase activity, these two proteins also suppress signalling via a second mechanism, making them distinct from the rest of SOCS family. This second mechanism involves a short motif immediately upstream of the SH2 domain, known as the KIR (kinase-inhibitory region) [15, 16] . This enables SOCS1 and SOCS3 to directly inhibit the kinase activity of JAK and is their dominant mode of action in vivo. The molecular mechanism of this mode of inhibition was determined recently upon solving the crystal structure of SOCS3 bound to JAK2 [17] and is described below.
The mechanism of JAK inhibition by SOCS3
In the late 1990s, Yoshimura and colleagues first demonstrated that overexpression of either SOCS3 or SOCS1 leads to reduced JAK autophosphorylation as well as reduced levels of phosphorylated STAT downstream [15, 16] . Using mutagenesis, they identified a 12-amino-acid region upstream of the SH2 domain in both SOCS1 and SOCS3 that is required for this activity and hypothesized that these two SOCS proteins may bind directly to JAKs and inhibit their catalytic activity. Our recent biochemical [18] and structural [17] data support Yoshimura's hypothesis and have uncovered the molecular mechanism of SOCS3-(and, by analogy, SOCS1-) mediated inhibition of JAK.
Using [18] . The IC 50 was identical using a number of different substrates including proteins, peptides and synthetic polypeptides (poly-Glu 4 Tyr), indicating that SOCS3 was interacting directly with JAK and not with substrate. Point mutations in either the KIR (F25A) or the SH2 domain (R71A) completely abrogated this inhibition. These data fit the previously proposed model in which SOCS3 tethers itself to JAK by binding phosphotyrosine residues in the JAK activation loop via its SH2 domain and then blocking the JAK active site using its KIR. Surprisingly, however, the addition of a large molar excess of a competitor phosphopeptide did not interfere with JAK inhibition, seemingly contradicting the R71A mutation data, and implying that SOCS3 does not bind JAK2 using the canonical phosphotyrosine-binding site of the SH2 domain. The explanation for this came when Kershaw et al. [17] solved the structure of SOCS3 bound to JAK2 using X-ray crystallography.
The SOCS3-JAK2 crystal structure shows that SOCS3 does not interact with phosphotyrosine residues on JAK2 ( Figure 1 , inset). Instead, although SOCS3 binds JAK via its SH2 domain, it does so using a surface that is on the opposite side of this domain when compared with the canonical phosphotyrosine-binding groove. This surface consists of the ESS (the extended SH2 subdomain, an α-helical N-terminal extension to the SH2 domain found in all SOCS proteins), the loop between β-sheets B and C in the SH2 domain, the KIR and regions in between. This leaves the phosphotyrosinebinding groove open and able to bind a different ligand. Indeed, the structure solved by Kershaw et al. [17] contained a phosphopeptide from the IL (interleukin)-6 receptor gp130 chain that was found to be located in the phosphotyrosinebinding groove of the SOCS3 SH2 domain and did not interfere with JAK binding.
SOCS3 uses a largely hydrophobic surface to anchor to the JAK2 catalytic domain and then inhibits the enzyme by placing the KIR {residues 22-29 ( Figure 2A) , which is unstructured in the absence of JAK [19, 20] } into the substrate-binding groove. The first residue of the KIR (Leu 22 ) occupies the 'P + 1' binding pocket of JAK (Figure 2B ), where the residue immediately C-terminal to the substrate tyrosine residue is predicted to bind. SOCS3 thereby inhibits JAK by blocking substrate from docking. This proposed mode of action has been supported biochemically in two ways. (i) Mutant forms of SOCS3 that incorporate a tyrosine residue one to three residues N-terminal to Leu 22 of the KIR (i.e. residues 19-21 of the protein) are extremely efficient substrates for JAKcatalysed phosphorylation ( Figure 2C ) [17] . This is consistent with a model in which JAK2 remains catalytically active with SOCS3 bound, but cannot phosphorylate substrates because SOCS3 blocks them from binding; however, when SOCS3 itself is the substrate, then catalysis can proceed efficiently. (ii) Truncating the KIR by one or two residues results in a SOCS3 construct that can bind but no longer completely inhibit JAK. For example, when JAK2 is saturated with a fragment of SOCS3 lacking only the first residue of the KIR, it retains 25% of its activity. These data are consistent with a model in which truncated forms of SOCS3 cannot completely block substrate binding because of a reduced overlap between the KIR and the substrate ( Figure 2D ). In support of this, we found that when this overlap was reduced even further by using a C-terminally truncated form of the substrate, which only contained a single residue downstream of the tyrosine residue, inhibition was even less complete.
We highlight the fact that the only fragment of SOCS3 we have been able to crystallize in complex with JAK lacks the first 21 residues of the native protein. Our structure hints that residue 21 may bind in the tyrosine-binding pocket, thereby acting as a pseudosubstrate residue ( Figure 2D ). This is supported by the fact that a tyrosine residue placed at position 21 is an extremely efficient substrate [17] . Residue 21 in the native SOCS3 sequence is an arginine and in SOCS1 is a histidine and these are absolutely conserved throughout evolution. Both histidine and arginine have side chains that are long enough to access the tyrosine-binding pocket on JAK and also contain planar elements at their distal end that may stack on to Pro 1017 of JAK2 in the same way that a substrate tyrosine would. Despite this, Arg 21 of SOCS3 did not provide any extra affinity for JAK2 and was not required for complete inhibition. Therefore any interactions it makes seem to be dispensable for SOCS3 function.
Overall, our structural and biochemical data strongly imply that SOCS3 inhibits JAK by blocking substrate binding, although one interesting conundrum remains: a steady-state analysis of SOCS3 inhibition of JAK2 revealed that SOCS3 displays non-competitive inhibitory kinetics with regard to both ATP and substrate [18] . Whereas the SOCS3-JAK2 structure shows that SOCS3 does not compete with ATP binding, it does appear to compete with substrate binding and should therefore give rise to competitive kinetics when analysed under steady-state conditions. The reason for this disparity is currently unclear, but the explanation may lie in the fact that, whereas the KIR competes with substrate for binding, SOCS3 is tethered to JAK by a much larger surface that provides the majority of the affinity and does not compete with substrate. 
Comparison with other kinase inhibitory systems
The SOCS3-JAK2 structure revealed parallels between SOCS3 inhibition of JAK and other pseudosubstrate-based kinase inhibitory systems, in particular Grb14 (growth factor receptor-bound protein 14) inhibition of the IRK (insulin receptor kinase). Grb14 also acts by blocking substrate binding using a KIR-like region [termed the BPS region for 'between PH (pleckstrin homology) and SH2 region']. This region is unstructured in the absence of IRK in the same way that the SOCS3 KIR is unstructured in the absence of JAK [21] . However, Grb14 anchors itself to IRK by using its SH2 domain to bind phosphotyrosine residues on IRK. In contrast, SOCS3 anchors itself to a different surface on JAK2 via a phospho-independent mechanism. The surface targeted by SOCS3 is centred upon the N-terminal section of the αG-helix in JAK2 ( Figure 3C ) [and the important GQM (GlyGlu-Met) motif immediately upstream, see the next section]. This helix is structurally conserved among kinases and is close to the substrate-binding site, therefore it is targeted by a number of pseudosubstrate-based inhibitors of other kinases, including the autoinhibitory regions of type I and type II PAKs (p21-associated kinases) [22, 23] and the viral protein K3L from vaccinia virus that inhibits protein kinase R (or double-stranded-RNA-dependent protein kinase) [24] .
SOCS3 targets specific JAK-receptor pairs
There are four mammalian JAKs [JAK1-JAK3 and TYK2 (tyrosine kinase 2)] and these are unique among kinases in containing an approximately 20-residue insertion in their kinase domain structures between the F-helix and the aforementioned G-helix, termed the JAK insertion loop [25] . The last three residues of this insertion are GQM in JAK1, JAK2 and TYK2, but these are not conserved in JAK3 ( Figure 3A ). Using in vitro inhibition assays, we showed that SOCS3 inhibits JAK1, JAK2 and TYK2 directly, with similar affinity, but does not inhibit JAK3 [18] and that this inhibition requires the presence of this GQM motif. Mutating either the glycine or the methionine residue within the JAK2 GQM motif to the corresponding residues in JAK3 (aspartate and proline respectively) generates a mutant JAK2 protein that is fully active, but no longer responsive to SOCS3-mediated inhibition. Our crystal structure confirms that this region encoding the GQM motif is important for the SOCS-JAK interaction. An examination of JAK evolution is telling in this regard. Only vertebrates have evolved an expanded JAK system, consisting of four JAKs, whereas lower organisms, such as insects, contain only a single JAK homologue (Hopscotch in Drosophila). Likewise, only vertebrates have evolved SOCS1 and SOCS3 homologues with a KIR ( Figure 3B ). The GQM motif is conserved in JAK1, JAK2 and TYK2 in all vertebrates and is always absent from JAK3 ( Figure 3A) . Therefore vertebrates have evolved a more complex JAK repertoire alongside the ability to inhibit only a subset of them. The advantage of having JAK3 insensitive to SOCS-mediated inhibition remains to be determined.
In addition to specificity towards particular JAKs, SOCS3 also targets particular cytokine receptors by binding specific phosphotyrosine motifs (Table 1 ). These include the receptors for G-CSF (granulocyte colony-stimulating factor) [26] and leptin [27] and, most importantly, the gp130 shared coreceptor [28] which is used by a number of different cytokines including IL-6, IL-11, LIF (leukaemia-inhibitory factor), G-CSF and OSM (oncostatin M). The crystal structure of the SOCS3-JAK2 complex shows that SOCS3 can bind JAK2 and gp130 at the same time, using two distinct surfaces. In vivo, JAK is also bound to gp130 (via its FERM domain), setting up a three-way interaction, whereby each component of the system can interact with the other two simultaneously. This implies that, whereas SOCS3 binds gp130 or JAK2 alone with moderate affinity (0.1-1 μM), it will bind a JAK2-gp130 heterodimer with much higher avidity. The dissociation constant could be as strong as 1 pM, given that, theoretically, a ligand that binds two individual and non-overlapping sites on a receptor simultaneously does so with an affinity that approaches the product of the individual K d values rather than the sum. Further work is required to determine whether this is truly the case with SOCS3.
Taken together, the affinity of SOCS3 for particular JAKs and particular receptors allows it to target certain signalling pathways with high specificity. These pathways are those that signal through JAK1, JAK2 or TYK2 via a receptor that contains a SOCS3-binding motif. Currently, there are a number of cytokines that fit these criteria, namely IL-6, IL-11, G-CSF, LIF, OSM, leptin and potentially EPO (erythropoietin). The importance of SOCS3 for IL-6, LIF, leptin and G-CSF has been demonstrated by genetic deletion (Table 1 ).
It appears likely that SOCS1 acts via the same mechanism as SOCS3. Not only does the KIR of SOCS1 share a high degree of sequence similarity with that of SOCS3, but the amino acid residues that form the three-dimensional surface of SOCS3 that contacts JAK are almost all conserved in SOCS1 [17] . Therefore we would predict that SOCS1 will target the same JAKs as SOCS3 (JAK1, JAK2 and TYK2), but will target different receptors due to sequence divergence within the phosphotyrosine-binding grooves of their SH2 domains. To date, little is known about which sites on which receptors are SOCS1 targets, with the exception of pTyr 441 of the interferon-γ receptor. It is of great importance to determine which JAKs and receptors are targeted by SOCS1 in order to determine the full repertoire of cytokines regulated by these two potent and important signalling inhibitors. Our current efforts lie in this direction.
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